Blurred vision or a dark patch on the iris are symptoms of intraocular (uveal) melanoma, a rare eye disease. Intraocular melanoma can be treated with a variety of methods, including eye exams. Surgery, radiation therapy, photocoagulation, and thermotherapy are among the usual therapies, according to the National Cancer Institute (NCI). Other treatments are being investigated in clinical studies alongside these traditional medicines. Nivolumab, for example, is an immunotherapy medicine that has been found to help persons with uveal melanoma by improving their general immunity. It is currently in Phase II clinical trials.
Intraocular Melanoma Treatment Market Drivers
In addition, a combination of Ipilimumab and Nivolumab, as well as Selumetinib, are being evaluated for uveal melanoma. Selumetinib is a targeted therapy that has been shown to decrease the progression of eye melanoma, while nivolumab in conjunction with lpilimumab is being tested in a Phase II clinical trial to treat uveal melanoma.
Understanding the molecular characteristics of intraocular melanoma treatment market tumours through genetic alternations and mutations studies in patients, as well as novel therapies based on inhibition mechanisms of expression of growth factor receptors such as c-Met and c-Kit, are being investigated to bring better treatment options to intraocular melanoma patients.
Read More: https://bit.ly/3nCytWf
